Atossa

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Retrieved on: 
Tuesday, April 9, 2024
Plasma, MRI, Neoplasm, Atossa, Ki-67, Associate, RECIST, Magnetic resonance imaging, Incidence, Patient, MD, Woman, AACR, Clinical trial, Therapy, Breast cancer, Safety, Division, Recurrence, Exemestane, Annual general meeting, Medical imaging

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.

Key Points: 
  • SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study.
  • At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months.

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Comparison, Atossa, Patient, Mayo Clinic, Neoplasm, Ductal carcinoma, Woman, AACR, CFA, Clinical trial, Therapy, Breast cancer, Safety, DCIS, FDA, Exemestane, Breast, Annual general meeting, Pharmaceutical industry

SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.

Key Points: 
  • SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.
  • Full enrollment was achieved in November 2023 and data is expected in the second half of 2024.
  • Factors contributing to the increased operating expenses in the year ended December 31, 2023 are explained below.
  • The following table provides a breakdown of major categories within R&D expense for the years ended December 31, 2023 and 2022, together with the dollar change in those categories (in thousands):

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Retrieved on: 
Monday, March 18, 2024
Atossa, Breast cancer, Therapy

SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on using (Z)-endoxifen to prevent and treat breast cancer.
  • As previously disclosed, on September 26, 2023, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
  • To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days.

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Harvard College, Health, Internal medicine, Public health, Disease, Atossa, Oncology, Patient, Cornell University, Weill Cornell Medical Center, Woman, Helsinki University Central Hospital, Clinical trial, Therapy, Breast cancer, Hematology, Weill Cornell Medicine, Pharmaceutical industry

Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.

Key Points: 
  • Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.
  • “We are pleased to welcome Dr. Cigler to our board of directors,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer.
  • “Tessa works daily with breast cancer patients and knows firsthand the critical need for more effective and tolerable treatment options.
  • While progress has been made over the past decade, breast cancer remains a deadly disease for hundreds of thousands of women globally each year.

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Breast cancer, Cancer, Woman, Neoadjuvant therapy, Atossa, AACR, Exemestane, Therapy, Health, Patient, Estrogen receptor

The EVANGELINE study is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.

Key Points: 
  • The EVANGELINE study is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer.
  • “We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
  • Organized by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world.

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Breast, Woman, Health Canada, Research, Therapy, Conduct, Clinical trial, Comparison, Breast cancer, Administration, Patient, Triple-negative breast cancer, G&A, Ductal carcinoma, Neoplasm, Atossa, Seminal vesicles, Partnership, R, Research and development, Estrogen receptor, TNBC, Pharmaceutical industry, Fine chemical, Birth control, DCIS

Four ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS

Key Points: 
  • Four ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS
    SEATTLE, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended September 30, 2023, and provides an update on recent company developments.
  • Key developments from Q3 2023 and year to date include:
    80% Enrollment in Ongoing Phase 2 Karisma-Endoxifen Clinical Trial – the study is investigating (Z)-endoxifen in premenopausal women with measurable breast density.
  • Participants receive daily doses of (Z)-endoxifen for six months, over the course of which mammograms are conducted to measure reduction in breast density.
  • Full enrollment is expected by the end of 2023 and data is expected in the second half of 2024.

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

Retrieved on: 
Thursday, November 9, 2023
Atossa, Doctor of Philosophy, Lindner, Computational biology, Drug development, Growth, Medicine, Market capitalization, Breast cancer, Partner, CFA, Therapy, Chemistry, Pharmaceutical industry, MD

Mr. Finn has more than 25 years of experience in the financial industry with a focus on early to mid-stage biotech and technology companies.

Key Points: 
  • Mr. Finn has more than 25 years of experience in the financial industry with a focus on early to mid-stage biotech and technology companies.
  • Mr. Finn currently serves as Executive Vice President and Chief Investment Officer at Vantage Consulting Group, an investment advisory firm.
  • In this role, he directs investment strategy, asset allocation, manager selection and portfolio construction.
  • “We are pleased to welcome Jon, who has extensive experience working with clinical stage biotechnology companies to accelerate growth and commercialize assets, to our board of directors,” said Steven Quay, MD, PhD, Atossa’s President and Chief Executive Officer.

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Retrieved on: 
Monday, October 30, 2023
DCIS, FDA, NCI, Atossa, Testosterone, Biomarker, SERM, MD, Breast disease, Growth, Ductal carcinoma, Disease, Risk, Tamoxifen, National Cancer Institute, Breast cancer, SAN, Woman, Safety, Anastrozole, Patient, Toxicity, Breast, Pharmaceutical industry, Birth control

SAN FRANCISCO, Oct. 30, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. The study is evaluating three investigational endocrine therapy arms: (Z)-endoxifen, a selective estrogen receptor modulator (SERM) in development by Atossa Therapeutics (Nasdaq: ATOS); HAVAH T+Ai™, a proprietary combination of testosterone (T) and anastrozole (Ai) that targets the androgen and estrogen receptor pathways in development by Havah Therapeutics; and ORSERDU® (elacestrant), the only FDA approved oral selective estrogen receptor degrader (oSERD) in development by Stemline Therapeutics Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group. 

Key Points: 
  • Surgery is the current standard treatment for DCIS even though many patients never progress to breast cancer, which means that patients are often over-treated with invasive procedures.
  • A key element in reducing overtreatment of DCIS is identifying biomarkers that reflect the risk of progression so that those with low-risk lesions are spared surgery.
  • RECAST DCIS features the assessment of imaging and molecular-based biomarkers in addition to evaluating new investigational agents in this setting.
  • The three collaborators for this trial, Atossa Therapeutics, Havah Therapeutics, and Stemline, all aim to find alternative solutions for DCIS patients and are providing different agents for assessment.

Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

Retrieved on: 
Tuesday, October 17, 2023
Software, Research, Other Health, Hardware, Pharmaceutical, Consumer, Technology, Medical Devices, Science, Biotechnology, Seniors, Health, Other Science, Multimedia, Arthur Andersen, Acquisition, HOPE, Therapy, Safety, FDA, IPO, CNS, CFO, CPA, Patient, Pharmaceutical industry, Cognito, Atossa

Cognito Therapeutics , a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company.

Key Points: 
  • Cognito Therapeutics , a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company.
  • View the full release here: https://www.businesswire.com/news/home/20231017630946/en/
    Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito.
  • Most recently, he served as CFO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage oncology company.
  • “We are delighted to welcome Greg, who brings decades of expertise leading high-performing teams in the private and public sectors,” said Brent Vaughan, Chief Executive Officer at Cognito Therapeutics.

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

Retrieved on: 
Monday, September 18, 2023
Therapy, Conference, Breast cancer, Pharmaceutical industry, Atossa

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.

Key Points: 
  • SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.
  • Details of the company's participation are as follows:
    Format: Fireside Chat with Chief Executive Officer Steven Quay, M.D., Ph.D.
  • ET
    Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at https://investors.atossatherapeutics.com .
  • The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.